País: Australia
Idioma: inglés
Fuente: Department of Health (Therapeutic Goods Administration)
Alendronate sodium monohydrate
Aspen Pharma Pty Ltd
Medicine Registered
ALENDRO ONCE WEEKLY- Consumer Medicine Information Page 1of 4 ALENDRO ONCE WEEKLY alendronate sodium monohydrate CONSUMER MEDICINE INFORMATION (CMI) WHAT IS IN THIS LEAFLET This leaflet answers some common questions about ALENDRO ONCE WEEKLY. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking ALENDRO ONCE WEEKLY against the benefits they expect it will have for you. TALK TO YOUR DOCTOR OR PHARMACIST IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT ALENDRO ONCE WEEKLY ARE USED FOR ALENDRO ONCE WEEKLY is used to treat osteoporosis in men and postmenopausal women. This condition is caused by changes in the way bone is normally maintained. UNDERSTANDING BONE Bone is living, growing tissue. Throughout life, our bodies are breaking down old bone and rebuilding new bone in a continuous cycle. Until our late 20s, while bones are still developing, we gain bone by building more than we lose. From then until about age 35 the process is usually in balance, so that the amount of bone lost is about equal to the amount that is replaced. After about age 35 this balance is disturbed, with bone loss occurring at a slightly faster rate than it can be replaced. In women, after menopause, hormonal changes cause bone loss at an even faster rate. When bone loss is excessive, bones can become thinner and weaker, and therefore are more likely to break. OSTEOPOROSIS "Osteo" means bone, and "porosis" means something that has holes in it, like a sponge. Therefore, osteoporosis is a disease w Leer el documento completo
ALENDRO- Product Information Page 1 of 17 Alendro PRODUCT INFORMATION NAME OF THE DRUG Alendronic acid (as alendronate sodium monohydrate). The chemical name for alendronate sodium monohydrate is (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt monohydrate. Its structural formula is: O II HO —P—ONa I H 2 N —CH 2 CH 2 CH 2 —C—OH H 2 0 I HO —P—OH II O C 4 H 12 NNaO 7 P 2 .H 2 O Molecular weight: 289.1 Cas No. 260055-05-8 DESCRIPTION Alendronate sodium monohydrate is a white, crystalline nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol and practically insoluble in chloroform. Alendro tablets come in three strengths and contain 10 mg, 40 mg or 70 mg of alendronic acid as alendronate sodium monohydrate. The tablets also contain the following excipients: croscarmellose sodium, microcrystalline cellulose, lactose and magnesium stearate. The tablets are gluten free. PHARMACOLOGY PHARMACODYNAMIC PROPERTIES. Alendronate is a bisphosphonate that, in animal studies, localises preferentially to sites of bone resorption, specifically under osteoclasts, and inhibits osteoclastic bone resorption with no direct effect on bone formation. Since bone formation and bone resorption are coupled, bone formation is also reduced, but less so than resorption, leading to progressive gains in bone mass (see Clinical trials). Following exposure to alendronate, normal bone is formed that incorporates alendronate into its matrix, where it is pharmacologically inactive. The relative inhibitory activities on bone resorption and mineralisation of alendronate and etidr Leer el documento completo